164 related articles for article (PubMed ID: 32211877)
21. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
22. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
[TBL] [Abstract][Full Text] [Related]
23. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS; Advani RH
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
[TBL] [Abstract][Full Text] [Related]
24. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
25. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.
Shankar AG; Kirkwood AA; Depani S; Bianchi E; Hayward J; Ramsay AD; Hall GW
Br J Haematol; 2016 May; 173(3):421-31. PubMed ID: 26996288
[TBL] [Abstract][Full Text] [Related]
26. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
[TBL] [Abstract][Full Text] [Related]
27. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
28. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS; Flerlage JE; Savage KJ; Akhtar S; Steiner R; Zhang XY; Dickinson M; Prica A; Major A; Hendrickson PG; Hopkins D; Ng A; Casulo C; Baron J; Roberts KB; Al Kendi J; Balogh A; Ricardi U; Torka P; Specht L; De Silva R; Pickard K; Blazin LJ; Henry M; Smith CM; Halperin D; Brady J; Brennan B; Senchenko MA; Reeves M; Hoppe BS; Terezakis S; Talaulikar D; Picardi M; Kirova Y; Fergusson P; Hawkes EA; Lee D; Doo NW; Barraclough A; Cheah CY; Ku M; Hamad N; Mutsando H; Gilbertson M; Marconi T; Viiala N; Maurer MJ; Eichenauer DA; Hoppe RT;
J Clin Oncol; 2024 Mar; ():JCO2301655. PubMed ID: 38531001
[TBL] [Abstract][Full Text] [Related]
29. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
30. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
31. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
[TBL] [Abstract][Full Text] [Related]
33. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
[TBL] [Abstract][Full Text] [Related]
34. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Agbay RLMC; Loghavi S; Zuo Z; Fayad L; Dabaja B; Medeiros LJ; Khoury JD
Am J Surg Pathol; 2018 Apr; 42(4):492-499. PubMed ID: 29309302
[TBL] [Abstract][Full Text] [Related]
35. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
Molin D; Linderoth J; Wahlin BE
Br J Haematol; 2017 May; 177(3):449-456. PubMed ID: 28233899
[TBL] [Abstract][Full Text] [Related]
36. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
[TBL] [Abstract][Full Text] [Related]
37. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
[TBL] [Abstract][Full Text] [Related]
38. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
40. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
Pinnix CC; Osborne EM; Chihara D; Lai P; Zhou S; Ramirez MM; Oki Y; Hagemeister FB; Rodriguez AM; Samaniego F; Fowler N; Romaguera JE; Turturro F; Fayad L; Westin JR; Nastoupil L; Neelapu SS; Cheah CY; Dabaja BS; Milgrom SA; Smith GL; Horace P; Milbourne A; Wogan CF; Ballas L; Fanale MA
JAMA Oncol; 2016 Aug; 2(8):1065-9. PubMed ID: 27227654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
